These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. CT characteristics predict the response to everolimus or sirolimus of renal angiomyolipomas in patients with tuberous sclerosis complex. Wang W; Guo H; Shi B; Sun H; Li H; Zhang Y; Cai Y Int Urol Nephrol; 2019 Apr; 51(4):671-676. PubMed ID: 30756282 [TBL] [Abstract][Full Text] [Related]
4. Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex. Wienecke R; Fackler I; Linsenmaier U; Mayer K; Licht T; Kretzler M Am J Kidney Dis; 2006 Sep; 48(3):e27-9. PubMed ID: 16931204 [TBL] [Abstract][Full Text] [Related]
5. Low-dose rapamycin reduces kidney volume angiomyolipomas and prevents the loss of renal function in a patient with tuberous sclerosis complex. Peces R; Peces C; Cuesta-López E; Pérez-Dueñas V; Vega-Cabrera C; Azorín S; Selgas R Nephrol Dial Transplant; 2010 Nov; 25(11):3787-91. PubMed ID: 20663789 [TBL] [Abstract][Full Text] [Related]
6. Role of mTOR inhibition in the treatment of patients with renal angiomyolipomas. Coombs EJ J Am Assoc Nurse Pract; 2013 Nov; 25(11):588-96. PubMed ID: 24170533 [TBL] [Abstract][Full Text] [Related]
7. [Rapamycin in the treatment of renal diseases associated with tuberous sclerosis complex]. Dun S; Zou LP; Zhang MN; Wang YY; He W; Chen HM; Hu LY; Chen XQ; Lu Q; Pang LY; Liu LY; Tang LN; Wang B Zhonghua Er Ke Za Zhi; 2019 Nov; 57(11):852-856. PubMed ID: 31665839 [No Abstract] [Full Text] [Related]
9. Microscopic Kidney Disease in Tuberous Sclerosis Complex and Treatment With mTOR Inhibition. Kronick J; Gabril MY; House AA Am J Kidney Dis; 2023 Dec; 82(6):772-775. PubMed ID: 37532078 [TBL] [Abstract][Full Text] [Related]
10. The efficacy of cannabidiol on renal angiomyolipoma and subependymal giant cell tumor volume in tuberous sclerosis complex. Barnett JR; Grinspoon RA; Harisinghani M; Caruso PA; Thiele EA J Clin Neurosci; 2020 Jul; 77():85-88. PubMed ID: 32409220 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of sirolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: a systematic review. Peng ZF; Yang L; Wang TT; Han P; Liu ZH; Wei Q J Urol; 2014 Nov; 192(5):1424-30. PubMed ID: 24813310 [TBL] [Abstract][Full Text] [Related]
12. Review of the Tuberous Sclerosis Renal Guidelines from the 2012 Consensus Conference: Current Data and Future Study. Kingswood JC; Bissler JJ; Budde K; Hulbert J; Guay-Woodford L; Sampson JR; Sauter M; Cox J; Patel U; Elmslie F; Anderson C; Zonnenberg BA Nephron; 2016; 134(2):51-58. PubMed ID: 27504842 [TBL] [Abstract][Full Text] [Related]
13. Effects of rapamycin on angiomyolipomas in patients with tuberous sclerosis. Cabrera López C; Martí T; Catalá V; Torres F; Mateu S; Ballarín Castán J; Torra Balcells R Nefrologia; 2011; 31(3):292-8. PubMed ID: 21629335 [TBL] [Abstract][Full Text] [Related]
14. Giant bilateral renal angiomyolipomas and lymphangioleiomyomatosis presenting after two successive pregnancies successfully treated with surgery and rapamycin. Peces R; Cuesta-López E; Peces C; Selgas R ScientificWorldJournal; 2011; 11():2115-23. PubMed ID: 22125460 [TBL] [Abstract][Full Text] [Related]
16. Metastatic breast carcinoma to renal angiomyolipomas in tuberous sclerosis. Williams TR; Oakes MF Urology; 2008 Feb; 71(2):352.e5-7. PubMed ID: 18308125 [TBL] [Abstract][Full Text] [Related]
17. The effect of sirolimus on angiomyolipoma is determined by decrease of fat-poor compartments and includes striking reduction of vascular structures. Watanabe EH; Coelho FMA; Filho HL; Balbo BEP; Neves PDMM; Franzin FM; Yamauchi FI; Onuchic LF Sci Rep; 2021 Apr; 11(1):8493. PubMed ID: 33875750 [TBL] [Abstract][Full Text] [Related]
18. Sirolimus can promote the disappearance of renal angiomyolipoma associated with tuberous sclerosis complex: a prospective cohort study. Dun S; Wang YY; Wan L; Wang QH; Lu Q; Yang XY; Zhang Q; Chen HM; Qiu LP; Zou LP World J Pediatr; 2024 Jun; 20(6):602-610. PubMed ID: 37773307 [TBL] [Abstract][Full Text] [Related]
19. Percutaneous cryoablation for tuberous sclerosis-associated renal angiomyolipoma with neoadjuvant mTOR inhibition. Krummel T; Garnon J; Lang H; Gangi A; Hannedouche T BMC Urol; 2014 Sep; 14():77. PubMed ID: 25258166 [TBL] [Abstract][Full Text] [Related]
20. Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors. Woodrum C; Nobil A; Dabora SL J Transl Med; 2010 Feb; 8():14. PubMed ID: 20146790 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]